Idiopathic pulmonary fibrosis challenges and opportunities for the clinician and investigator

Chest

Volumn 127, Issue 1, 2005, Pages 275-283

  Swigris, Jeffrey J ^a,d   Kuschner, Ware G ^b   Kelsey, Jennifer L ^c   Gould, Michael K ^b  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Interstitial; Lung diseases; Pulmonary fibrosis

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GAMMA1B INTERFERON; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; LUNG FIBROSIS; OPEN LUNG BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; CLINICAL TRIAL; MORTALITY; NOMENCLATURE; PATIENT SELECTION; RADIOGRAPHY;

CLINICAL TRIALS; HUMANS; PATIENT SELECTION; PROGNOSIS; PULMONARY FIBROSIS; TERMINOLOGY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 13844318314     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.1.275     Document Type: Review

References (52)

1. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151
2. Joint Statement of the American Thoracic Society and the European Respiratory Society: American Thoracic Society/ European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165:277-304
3. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance and pathologic classification. Am J Respir Crit Care Med 1998; 157:1301-1315
4. Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am J Surg Pathol 1994; 18:136-147
5. Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213-2217
6. Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160:899-905
7. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199-203
8. Nagai S, Kitaichi M, Itoh H, et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998; 12:1010-1019
9. Travis W, Matsui K, Moss J, et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns; survival comparisons with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24:19-33
10. Flaherty KR, Travis W, Colby T, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164:1722-1727
11. Katzenstein AL, Zisman D, Litzky L, et al. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 2002; 26:1567-1577
12. Coultas D, Zumwalt R, Black W, et al. The epidemiology of interstitial lung disease. Am J Respir Crit Care Med 1994; 150:967-972
13. Coultas D, Hughes M. Accuracy of mortality data for interstitial lung diseases in New Mexico, USA. Thorax 1996; 51:717-720
14. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171-1181
15. Flaherty KR, Toews GB, Lynch JP III, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110:278-282
16. Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164: 193-196
17. Joint Statement of the American Thoracic Society and the European Respiratory Society: idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am J Respir Crit Care Med 2000; 161:646-664
18. Mapel D, Samet J, Coultas D. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present and future. Chest 1996; 110:1058-1067
19. Johnston I, Prescott R, Chalmers J, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997; 52:38-44
20. Johnston ID, Gomm S, Kalra A. The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom. Eur Respir J 1993; 6:891-893
21. Raghu G, Mageto YN, Lockhart D, et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999; 116:1168-1174
22. Peckham R, Helman D, Shorr A. Potential limitations of clinical criteria for the diagnosis of idiopathic pulmonary fibrosis [abstract]. Chest 2002; 122:478
23. MacDonald S, Rubens M, Hansell DM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001; 221:600-605
24. Hunninghake GW, Lynch D, Galvin J, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003; 124:1215-1223
25. Laupacis A, Sekar N, Steill I. Clinical prediction rules: a review and suggested modifications of methodologic standards. JAMA 1997; 277:488-494
26. Boomars KA, Wagenaar SS, Mulder PC, et al. Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax 1995; 50:1087-1092
27. Gay S, Kazerooni E, Toews G, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157:1063-1072
28. King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164:1025-1032
29. Nicholson A, Fulford L, Colby T, et al. The relationship between histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166:173-177
30. Flaherty KR, Mumford J, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543-548
31. Lama V, Flaherty KR, Toews G, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084-1090
32. Wells AU, Desai S, Rubens M, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167:962-969
33. Adamson I, Young L, Bowden D. Relationship of alveolar epithelial injury and repair to the induction of pulmonary fibrosis. Am J Pathol 1988; 130:377-383
34. Davies H, Richeldi L, Walters E. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database of Systematic Reviews 2003; 1
35. Richeldi L, Davies H, Ferrara G, et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database of Systematic Reviews 2003; 1
36. Lynch J III, White E, Flaherty K. Corticosteroids in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2001; 7: 298-308
37. Carrington C, Gaensler E, Coutu R, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801-809
38. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35:593-599
39. Tukiainen P, Taskinen E, Holsti P, et al. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38:349-355
40. Stack B, Choo-Kang F, Heard B. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972; 27:535-542
41. Raghu G, Depaso W, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled trial. Am Rev Respir Dis 1991; 144:291-296
42. Johnson M, Kwan S, Snell N, et al. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44:280-288
43. Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72:201-209
44. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161:1172-1178
45. Johnston ID, Prescott RJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management; Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997; 52:38-44
46. Temple R, Ellenberg S. Placebo-controlled trials and active-control trials in the evaluation of new treatments: part 1. Ethical and scientific issues. Ann Intern Med 2000; 133:455-463
47. Raghu G, Brown K, Bradford W, et al. A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350:125-133
48. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833
49. Lavori P, Rush A, Wisniewski S, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 2001; 50:792-801
50. DeVries J, Kessels B, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J 2001; 17:954-961
51. DeVries J, Seebregts A, Drent M. Assessing health status and quality of life in idiopathic pulmonary fibrosis: which measure should be used? Respir Med 2000; 94:273-278
52. Martinez T, Pereira C, dos Santos M, et al. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000; 117:1627-1632